BriaCell Therapeutics Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCTX research report →
Companywww.briacell.com
BriaCell Therapeutics Corp. , an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer.
- CEO
- William V. Williams
- IPO
- 2012
- Employees
- 16
- HQ
- West Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $7.40M
- P/E
- -0.26
- P/S
- 0.00
- P/B
- 0.36
- EV/EBITDA
- 0.61
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -221.75%
- ROIC
- -123.64%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-36,493,821 · -457.40%
- EPS
- $-86.25 · -44.50%
- Op Income
- $-37,732,298
- FCF YoY
- -16.32%
Performance & Tape
- 52W High
- $37.20
- 52W Low
- $2.98
- 50D MA
- $4.13
- 200D MA
- $7.16
- Beta
- 1.63
- Avg Volume
- 209.46K
Get TickerSpark's AI analysis on BCTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 24 | Lustig Marc | buy | 902,935 |
| May 14, 24 | Lustig Marc | buy | 902,935 |
| Dec 28, 22 | Bondarenko Jamieson | buy | 28,000 |
| Dec 23, 22 | Williams William V. | buy | 2,530 |
| Dec 20, 22 | Bondarenko Jamieson | buy | 22,000 |
| Aug 1, 22 | Bondarenko Jamieson | other | 0 |
| Aug 1, 22 | Bondarenko Jamieson | other | 250,000 |
| Aug 12, 21 | Bondarenko Jamieson | other | 70,000 |
| Mar 29, 21 | Bondarenko Jamieson | other | 150,000 |
| Aug 1, 22 | Lustig Marc | other | 0 |
Our BCTX Coverage
We haven't published any research on BCTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BCTX Report →